Europe
Hertfordshire Local Enterprise Partnership is to invest £1.2m into Stevenage Bioscience Catalyst (SBC) to help grow a world-class cell and gene therapy cluster.
BioCity, the pioneering life science incubator and business collective today releases its biennial publication, the UK Life Science Start-Up Report, an in-depth analysis of emerging businesses within the life sciences across the UK.
Zelluna Immunotherapy, a biopharma company developing T-cell receptor guided adoptive cell therapy products for the treatment of multiple solid cancers, and Glycostem Therapeutics BV, announce that they have entered into a development, license and supply agreement.
Epigenomics AG announced its financial results for the first nine months of 2019.
MorphoSys announced that the ongoing tafasitamab phase 3 B-MIND study has successfully passed the pre-planned, event-driven interim analysis for futility.
Bittium exhibits its innovative products and solutions for cardiology and neurology at Medica 2019, the leading international trade fair for the medical sector, on November 18-21 in Dusseldorf, Germany.
If successful, the CEO told BioSpace in an exclusive interview that Acelarin will break the glass ceiling as the first FDA-approved treatment for biliary tract cancer.
Amidst rumors that Novartis might be interested in an acquisition, The Medicines Company announced data from ORION-10, the second of three 19-month Phase III trials of inclisiran for lowering cholesterol.
CRISPR Therapeutics and Vertex Pharmaceuticals announced positive interim data from the first two patients in the companies’ ongoing Phase I/II clinical trials of its CRISPR/Cas9 gene-editing therapy CTX001.
PharmaMar had a notable presence at CTOS with two oral presentations and six posters on trabectedin and two posters on plocabulin.
PRESS RELEASES